Home
News
Create
Screeners
Insights
Prism Medico & Pharmacy
27.
40
+1.02
(+3.87%)
Market Cap
₹16.62 Cr
PE Ratio
26.65
Industry
Financial Services
Buy
Sell
Company Performance:
1D
+3.87%
1M
-4.83%
6M
+16.00%
1Y
+122.76%
5Y
+139.93%
View Company Insights
Latest news about Prism Medico & Pharmacy
Prism Medico and Pharmacy Limited Reports No Non-Convertible Securities Payable for Q1 FY27
2 days ago
Prism Medico and Pharmacy Limited has submitted a regulatory compliance intimation to BSE and MSEI under SEBI LODR Regulation 57(4), confirming that the company has not issued any non-convertible securities with payable interest, dividend, or principal amounts for the quarter from 01st April, 2026 to 30th June, 2026. The filing was made on 30th March, 2026, and signed by Director Davender Singh to ensure transparency regarding the company's debt securities position.
Prism Medico and Pharmacy Limited Clarifies Stock Price Movement Under SEBI Regulation 30
2 days ago
Prism Medico Submits Scrutinizer's Report with 99.98% EGM Approval Results
8 days ago
Prism Medico and Pharmacy Board Approves Rs. 25 Crore Equity Fundraising Through Preferential Issue
Feb 23, 2026
Prism Medico Reports Q3FY26 Loss of ₹1.34 Lakhs, Revenue Drops to ₹7.10 Lakhs
Feb 13, 2026
More news about Prism Medico & Pharmacy
14
Jan 26
Prism Medico and Pharmacy Limited Submits SEBI Depositories Compliance Certificate for Q3FY26
Prism Medico and Pharmacy Limited submitted its Q3FY26 confirmation certificate under SEBI Depositories Regulations for the quarter ended December 31, 2025. The filing, made on January 14, 2026, through RTA Purva Sharegistry, confirms no dematerialisation activity occurred during the quarter. The company maintains compliance with regulatory requirements across BSE and MSEI exchanges.
21
Nov 25
Prism Medico Reports Q2 Loss Amid Revenue Decline, Corrects Financial Statement Filing
Prism Medico & Pharmacy reported a net loss of ₹0.10 crore for Q2 ended September 30, with revenue declining 68.75% to ₹0.50 crore. Despite the quarterly loss, the company posted a half-year profit of ₹57.25 lakh. The operating profit margin fell to -20.00% from 40.88% in the previous quarter. The company also re-uploaded its complete financial statements to stock exchanges, addressing an initial filing error.
12
Sept 25
Prism Medico & Pharmacy Limited Reports Remarkable Q1 Performance with ₹65.73 Lakh Net Profit
Prism Medico & Pharmacy Limited announced a significant financial turnaround in Q1. Revenue from operations increased to ₹158.87 lakhs from ₹7.28 lakhs in the previous quarter. Net profit reached ₹65.73 lakhs, compared to ₹4.15 lakhs in Q4 and a loss of ₹9.00 lakhs year-over-year. The company demonstrated improved operational efficiency and cost management despite the revenue surge. The Board of Directors approved these unaudited standalone financial results, which were reviewed by auditors and submitted to stock exchanges in compliance with SEBI regulations.
Prism Medico & Pharmacy
27.
40
+
1.
02
(+
3.
87
%)
1 Year Returns:
+122.76%
Industry Peers
Bajaj Finance
826.85
(+
1.
17
%)
Shriram Finance
891.60
(-
0.
99
%)
Jio Financial Services
229.48
(-
1.
06
%)
Muthoot Finance
3,178.80
(-
2.
37
%)
Cholamandalam Investment
1,356.30
(-
1.
26
%)
SBI Cards
638.20
(+
0.
16
%)
Sundaram Finance
4,538.00
(-
1.
21
%)
M&M Financial Services
285.15
(-
1.
57
%)
Authum Inv & Infr
419.70
(-
2.
96
%)
Poonawalla Fincorp
393.30
(+
2.
78
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO